Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02775006 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma | terminated | Phase 3 | 45 | The Netherlands Cancer InstituteOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 |
| clinicaltrials |
| NCT02162537 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases(METAL2) | terminated | Phase 3 | 95 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01058759 | Taxotere-Enoxaparin-(ENOXA)-Study | terminated | Phase 3 | 14 | Hannover Medical SchoolOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00096265 | Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer | terminated | Phase 3 | 126 | National Cancer Institute (NCI)NIH | 2 | Mar 9, 2018 | clinicaltrials |
| NCT02134015 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)(HER3-Lung) | terminated | Phase 3 | 145 | Daiichi SankyoINDUSTRY | 10 | Jan 23, 2018 | clinicaltrials |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB(NeoIntercal) | terminated | Phase 2 / Phase 3 | 1 | AIO-Studien-gGmbHOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer(START2) | terminated | Phase 3 | 35 | EMD SeronoINDUSTRY | 2 | Aug 23, 2017 | clinicaltrials |
| NCT00526643 | CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients(CAPPA-2) | terminated | Phase 3 | 57 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01319669 | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy | terminated | Phase 2 / Phase 3 | 11 | Chinese Society of Lung CancerOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT01377376 | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib(ATTENTION) | terminated | Phase 3 | — | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
| NCT01015443 | Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population(INSPIRE) | terminated | Phase 3 | 285 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 5 | Oct 26, 2016 | clinicaltrials |
| NCT00190476 | Elderly NSCLC/D vs DP (JCOG0207) | terminated | Phase 3 | 230 | Japan Clinical Oncology GroupOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer(DISTAL-2) | terminated | Phase 3 | 84 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT02629848 | Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 3 | 401 | TakedaINDUSTRY | 0 | Dec 14, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00738881 | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer(MARVEL) | terminated | Phase 3 | 23 | National Cancer Institute (NCI)NIH | 2 | Oct 29, 2015 | clinicaltrials |
| NCT00460317 | MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | terminated | Phase 3 | 1,450 | AmgenINDUSTRY | 0 | Sep 7, 2015 | clinicaltrials |
| NCT00050336 | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) | terminated | Phase 3 | 702 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT01444118 | A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients(NSCLC) | terminated | Phase 3 | — | Bioven EuropeINDUSTRY | 1 | Jul 22, 2015 | clinicaltrials |
| NCT01282151 | TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer(TRAIL) | terminated | Phase 3 | 148 | Chonnam National University HospitalOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT01379976 | Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer | terminated | Phase 3 | 107 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Apr 24, 2015 | clinicaltrials |
| NCT00254891 | Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 3 | 828 | PfizerINDUSTRY | 26 | Mar 30, 2015 | clinicaltrials |
| NCT00254904 | Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC | terminated | Phase 3 | 839 | PfizerINDUSTRY | 24 | Mar 30, 2015 | clinicaltrials |
| NCT00535275 | NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy | terminated | Phase 3 | 88 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00633568 | Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer | terminated | Phase 3 | 125 | European Lung Cancer Working PartyOTHER | 4 | Feb 12, 2015 | clinicaltrials |
| NCT01046383 | Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients | terminated | Phase 3 | 16 | Immunotec Inc.INDUSTRY | 1 | Jan 21, 2015 | clinicaltrials |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | terminated | Phase 2 / Phase 3 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | terminated | Phase 3 | 681 | PfizerINDUSTRY | 26 | Jan 13, 2014 | clinicaltrials |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | terminated | Phase 3 | 583 | PfizerINDUSTRY | 27 | Jul 24, 2013 | clinicaltrials |
| NCT00442026 | Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC | terminated | Phase 3 | 106 | Hellenic Oncology Research GroupOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT00042315 | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 3 | 490 | QLT Inc.INDUSTRY | 0 | May 23, 2012 | clinicaltrials |
| NCT00437749 | A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | terminated | Phase 3 | 214 | CBA ResearchINDUSTRY | 1 | Sep 9, 2011 | clinicaltrials |
| NCT00234468 | Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | terminated | Phase 3 | 490 | AstraZenecaINDUSTRY | 1 | May 20, 2011 | clinicaltrials |
| NCT00273507 | Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3 | terminated | Phase 3 | 270 | Rigshospitalet, DenmarkOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00522639 | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation(FDG-PET lung) | terminated | Phase 3 | 120 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00243204 | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00290017 | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2019source: clinicaltrials